Soluble Fms-like tyrosine cinase 1 (sFLt-1) and antibody against AT1-receptor in preclempsia a comparison in a blind study design

Detalhes bibliográficos
Principais autores:	Verlohren, S, Herse, F, Wenzel, K, Redman, C, Dudennhausen, J, Dechend, R
Formato:	Journal article
Publicado em:	2008

Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) and Autoantibodies Against the AT1-Receptor in Preeclampsia in a Matched Pair, Blinded, Study Design.
por: Verlohren, S, et al.
Publicado em: (2008)

Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.
por: Herse, F, et al.
Publicado em: (2009)

Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia
por: Laura Ehrlich, et al.
Publicado em: (2017-04-01)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Natalie J. Hannan, et al.
Publicado em: (2017-05-01)

Altered Level of Soluble fms-like Tyrosine Kinase 1 (sFlt1) and Hypoxia Inducible Factor-1alpha (HIF-1alpha) in Normotensive Pregnancy and Preeclampsia
por: John Wantania, et al.
Publicado em: (2013-08-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
por: Ahmed M. Abbas, et al.
Publicado em: (2018-07-01)

Novel Ratio Soluble Fms-like Tyrosine Kinase-1/Angiotensin-II (sFlt-1/ANG-II) in Pregnant Women Is Associated with Critical Illness in COVID-19
por: Salvador Espino-y-Sosa, et al.
Publicado em: (2021-09-01)

The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience
por: Andrijana Müller, et al.
Publicado em: (2019-02-01)

Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt‐1 (Soluble fms‐Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio
por: Cecilia Villalaín, et al.
Publicado em: (2020-04-01)

Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies
por: Alice Hoeller, et al.
Publicado em: (2017-04-01)

Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia, and normal pregnancy
por: Muhammad Ilham Aldika Akbar, et al.
Publicado em: (2018-10-01)

CORRELATION BETWEEN FMS-LIKE TYROSINE KINASE-1 (SFLT-1) CELL-FREE MESSENGER RNA EXPRESSION AND FMS-LIKE TYROSINE KINASE-1 (SFLT-1) PROTEIN LEVEL IN SEVERE PREECLAMPSIA AND NORMAL PREGNANCY
por: Jeffry Iman Gurnadi, et al.
Publicado em: (2015-09-01)

Intraperitoneal Injection of High Tumor Necrosis Factor (TNF- α ) Serum Increase Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) and Blood Pressure of Pregnant Mice
por: Bramantyo Aji Wicaksono, et al.
Publicado em: (2015-05-01)

One step closer to a cure for preeclampsia? Boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1
por: Cerdeira, AS, et al.
Publicado em: (2020)

Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
por: Xinwen Chang, et al.
Publicado em: (2023-08-01)

Differences in levelFms-Like Tyrosine Kinase-1 (sFlt-1), soluble Endoglin (s-Eng), and Placental Growth Factor (PIGF) between Early Onset Preeclampsia and Late Onset Preeclampsia
por: Lita Nafratilova, et al.
Publicado em: (2018-10-01)

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
por: Kifle, MM, et al.
Publicado em: (2022)

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
por: Meron M. Kifle, et al.
Publicado em: (2022-06-01)

Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
por: Ping Tang, et al.
Publicado em: (2017-01-01)

sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics
por: Viktorija Tarasevičienė, et al.
Publicado em: (2016-01-01)

Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
por: Natalie J Hannan, et al.
Publicado em: (2018-01-01)

Distinct phenotypes in the preeclamptic-like mouse model induced by adenovirus carrying sFlt1 and recombinant sFlt1 protein
por: Yingying Wei, et al.
Publicado em: (2024-12-01)

Values of serum sFlt-1, PLGF levels, and sFlt-1/PLGF ratio in diagnosis and prognosis evaluation of preeclamptic patients
por: Xiaohe Zhu, et al.
Publicado em: (2020-10-01)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Park So-Yeon, et al.
Publicado em: (2008-07-01)

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.
por: Zeisler, H, et al.
Publicado em: (2016)

The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
por: Nurul Afzan Aminuddin, et al.
Publicado em: (2022-01-01)

The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy.
por: Yaling Zhai, et al.
Publicado em: (2020-01-01)

sFLT1, PlGF, the sFLT1/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies—A Review of the Literature
por: Ioakeim Sapantzoglou, et al.
Publicado em: (2023-06-01)

Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy.
por: Ya-Ling Zhai, et al.
Publicado em: (2014-01-01)

Human sFLT1 Leads to Severe Changes in Placental Differentiation and Vascularization in a Transgenic hsFLT1/rtTA FGR Mouse Model
por: Rebekka Vogtmann, et al.
Publicado em: (2019-03-01)

Circulating soluble fms-like tyrosine kinase-1 is placentally derived in normal pregnancy: first in vivo evidence
por: Cerdeira, AS, et al.
Publicado em: (2019)

Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
por: Laila Rahmi, et al.
Publicado em: (2016-01-01)

Perbandingan Kadar Soluble Fms-Like Tyrosine Kinase 1 (SFLT1) Serum Kehamilan Normal dengan Preeklamsi Berat Serta Hubungannya dengan Tekanan Darah dan Derajat Proteinuria
por: Amillia Siddiq, et al.
Publicado em: (2009-09-01)

A Second Trimester Prediction Algorithm for Early-Onset Hypertensive Disorders of Pregnancy Occurrence and Severity Based on Soluble fms-like Tyrosine Kinase 1 (sFlt-1)/Placental Growth Factor (PlGF) Ratio and Uterine Doppler Ultrasound in Women at Risk
por: Cristian Nicolae Chirilă, et al.
Publicado em: (2024-04-01)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsuzsanna K. Zsengellér, et al.
Publicado em: (2019-12-01)

Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia
por: Zeisler, H, et al.
Publicado em: (2016)

Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis.
por: Afuwape, A, et al.
Publicado em: (2003)

Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery
por: Orsel Isabelle, et al.
Publicado em: (2007-09-01)

Efficiency of sFlt-1/PlGF Ratio in Preeclampsia Diagnosis
por: Anca-Florina Tataru-Copos, et al.
Publicado em: (2022-09-01)

Predicting Preeclampsia Pregnancy Termination Time Using sFlt-1
por: Hiroaki Tanaka, et al.
Publicado em: (2022-06-01)

Soluble Fms-like tyrosine cinase 1 (sFLt-1) and antibody against AT1-receptor in preclempsia a comparison in a blind study design

Registros relacionados

Registros relacionados